016580 — Whanin Pharm Co Share Price
0.000.00%
Last trade - 00:00- KR₩202bn
- KR₩143bn
- KR₩230bn
- 88
- 86
- 51
- 92
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 8.25 | ||
| PEG Ratio (f) | 7.22 | ||
| EPS Growth (f) | 1.15% | ||
| Dividend Yield (f) | 1.51% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.55 | ||
| Price to Tang. Book | 0.56 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.83 | ||
| EV to EBITDA | 3.93 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 7.92% | ||
| Return on Equity | 8.18% | ||
| Operating Margin | 12.18% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 159,176.97 | 171,705.4 | 177,775.7 | 198,934.73 | 230,393.58 | 443,200 | 468,250 | 8.3% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -12.14 | +22.27 | +13.78 | -4.62 | +21.1 | -27.5 | +12.79 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Whanin Pharm Co Ltd is a Korea-based company engaged in the manufacturing of pharmaceutical products. The Company's products mainly include mental illness treatments, antidepressants, anti-schizophrenia drugs, cognitive improvement drugs, dementia treatments, anticonvulsants, digestive system drugs, antibiotics, antipyretics and analgesics, anti-inflammatory drugs, endocrine system drugs, respiratory system drugs and circulatory disorder drugs, ulcer treatment, liver protection and osteoporosis prevention treatment. The Company is also engaged in the real estate leasing business.
Directors
- Won Beom Lee PRE (38)
- Gye Gwan Lee VMG (67)
- Byeong Yeon Yoo VPR (61)
- Byeong Rak Ahn MDR (54)
- Jong Su Kim MDR (55)
- Yun Bae Kim MDR (53)
- Seung Won Lee OTH (52)
- Dong Su Lee OTH (47)
- Seung Sik Lee OTH (50)
- Gwang Su Ha NID (58)
- Gi Ok Jang NID (66)
- Byeong Mu Lee NID (41)
- Jeom Gyu Lee NID (53)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- December 16th, 1982
- Public Since
- July 3rd, 1996
- No. of Shareholders
- 15,244
- No. of Employees
- 663
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Korea Exchange - KSE
- Shares in Issue
- 15,267,070
- Address
- 117, Saemal-Ro, Songpa-Gu, SEOUL, 05809
- Web
- https://www.whanin.com
- Phone
- +82 24053000
- Auditors
- Deloitte Anjin LLC
Upcoming Events for 016580
Q4 2024 Whanin Pharm Co Ltd Earnings Release
Whanin Pharm Co Ltd Annual Shareholders Meeting
Similar to 016580
Aprogen Biologics
Korea Exchange - KSE
Boryung
Korea Exchange - KSE
Bukwang Pharm Co
Korea Exchange - KSE
Chong Kun Dang Pharmaceutical
Korea Exchange - KSE
CKD Bio
Korea Exchange - KSE
FAQ
What is the Whanin Pharm Co share price?
As of Today at 24:06 UTC, shares in Whanin Pharm Co are trading at KR₩13,250. This share price information is delayed by 15 minutes.
How has the Whanin Pharm Co share price performed this year?
Shares in Whanin Pharm Co last closed at KR₩13,250 and the price had moved by -3.63% over the past 365 days. In terms of relative price strength the Whanin Pharm Co share price has underperformed the FTSE Developed Asia Pacific Index by -18.46% over the past year.
What are the analyst and broker recommendations for Whanin Pharm Co?
The overall consensus recommendation for Whanin Pharm Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Whanin Pharm Co dividend yield?
The Whanin Pharm Co dividend yield is 2.26% based on the trailing twelve month period.
Does Whanin Pharm Co pay a dividend?
Last year, Whanin Pharm Co paid a total dividend of KR₩300, and it currently has a trailing dividend yield of 2.26%. We do not have any data on when Whanin Pharm Co is to next pay dividends.
When does Whanin Pharm Co next pay dividends?
We do not have data on when Whanin Pharm Co is to next pay dividends. The historic dividend yield on Whanin Pharm Co shares is currently 2.26%.
How do I buy Whanin Pharm Co shares?
To buy shares in Whanin Pharm Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Whanin Pharm Co?
As of the previous close price of KR₩13,250, shares in Whanin Pharm Co had a market capitalisation of KR₩202bn.
Where are Whanin Pharm Co shares listed?
Here are the trading details for Whanin Pharm Co:
- Country of listing: Korea, Republic of
- Exchange: KSC
- Ticker Symbol: 016580
What kind of share is Whanin Pharm Co?
Based on an overall assessment of its quality, value and momentum Whanin Pharm Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Whanin Pharm Co share price forecast for 2024?
The analyst consensus target price for shares in Whanin Pharm Co is KR₩25,000. That is 88.68% above the last closing price of KR₩13,250.
Analysts covering Whanin Pharm Co currently have a consensus Earnings Per Share (EPS) forecast of KR₩1,463 for the next financial year.
Find out moreWhat is the trend in the Whanin Pharm Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Whanin Pharm Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -12.55%.
As of the last closing price of KR₩13,250, shares in Whanin Pharm Co were trading -7.83% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Whanin Pharm Co PE Ratio?
The Whanin Pharm Co PE ratio based on its reported earnings over the past 12 months is 8.25. The shares last closed at KR₩13,250.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Whanin Pharm Co?
Whanin Pharm Co's management team is headed by:
- Won Beom Lee - PRE
- Gye Gwan Lee - VMG
- Byeong Yeon Yoo - VPR
- Byeong Rak Ahn - MDR
- Jong Su Kim - MDR
- Yun Bae Kim - MDR
- Seung Won Lee - OTH
- Dong Su Lee - OTH
- Seung Sik Lee - OTH
- Gwang Su Ha - NID
- Gi Ok Jang - NID
- Byeong Mu Lee - NID
- Jeom Gyu Lee - NID